TPST

News

globenewswire.comTempest Therapeutics Appoints Drake Richey and John Yee, MD, MPH to Board of Directorsglobenewswire.comJun 4

globenewswire.comTempest Therapeutics Announces Warrant Exercise for Approximately $2 Million in Gross Proceedsglobenewswire.comMay 29

globenewswire.comTempest Reports First Quarter 2026 Financial Results and Provides Business Updateglobenewswire.comMay 14

globenewswire.comTempest Presents Clinical Update at ISCT 2026 Annual Meetingglobenewswire.comMay 6

globenewswire.comTempest to Advance Dual-Targeting CAR-T Platform with Clinical Update at ISCT 2026 Annual Meetingglobenewswire.comApr 29

Trade TPST

About Tempest Therapeutics, Inc.

Tempest Therapeutics Inc. is an oncology company, currently in the clinical development phase, dedicated to advancing novel small molecule drugs designed to combat cancer. The firm's pipeline highlights two key therapeutic candidates: TPST-1495, a compound functioning as a dual inhibitor of EP2 and EP4 receptors (which are implicated in prostaglandin E2 signaling), currently undergoing initial human trials for solid tumor indications. The second candidate, TPST-1120, is a targeted blocker of peroxisome proliferator-activated receptor alpha, also progressing through Phase 1 studies for solid tumors. Beyond these clinical assets, Tempest is exploring TREX-1, a pivotal cellular enzyme known for its role in regulating the innate immune response within cancerous growths. Established in 2011, Tempest Therapeutics Inc. is headquartered in South San Francisco, California, having previously operated as a subsidiary of Inception Sciences, Inc.

CEO: Matthew Angel
IPO Date: Nov 12, 2012

Market Data

Open: $1.24
High: $1.29
Low: $1.24
Volume: 70.2K
52W High: $12.23
52W Low: $1.23

Valuation

Market Cap: $5.6M
Enterprise Value: $12M

Financials

Free Cash Flow: $-27M
Revenue: $0
Net Income: $-26M
Cash: $7.7M
Debt: $8.1M

Events

EarningsAug 10

EPS est. -0.3